Trial Profile
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs TAK 754 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; First in man
- Sponsors Baxalta; Shire; Takeda
- 07 Apr 2023 Planned End Date changed from 30 Sep 2026 to 24 Apr 2025.
- 07 Apr 2023 Planned primary completion date changed from 8 Jul 2024 to 24 Apr 2025.
- 23 Nov 2021 Planned primary completion date changed from 30 Sep 2021 to 8 Jul 2024.